Context
Pharma Deutschland e.V., a German pharmaceutical industry association, runs a China Working Group for its member companies. On 24 September 2026 Chenchao Liu gave the talk “China 2026/2027: Political developments and strategic choices for the German pharma industry” to the group. The session was held online, with 62 registrations from 33 organisations, mostly from regulatory affairs and other functional roles in pharmaceutical companies.
The talk
The talk placed political developments in Berlin, Brussels and Beijing in context and derived consequences for the product, market and partner decisions of German pharma companies.
-
China: Reimbursement and market access.
-
Europe: Security of supply.
-
Regulation: Recent regulatory changes.


What the reference letter records
-
Key message: The China decision is made product by product, not across the board.
-
Preparation: Content and format were agreed in advance, slides were provided on time and participants received a version with sources after the session.
-
Response: The response was positive, also among participants outside strategy functions; several asked for the working group to continue.
-
Recommendation: Pharma Deutschland recommends Chenchao Liu as a speaker on health and industrial policy developments in China and their consequences for European pharma companies. He has supported the working group with expert input since it was set up in 2024. This is a speaking reference, not a client engagement.
